What's this project about?
Mutations in the KRAS gene are found in 20 to 25 percent of lung cancers. These cancers do not respond well to standard lung cancer treatments.
Recently there have been important developments in two types of treatment approaches. It’s the job of the Dream Team to find the best way to combine those treatments and create better outcomes for people with the KRAS mutation.
Sign up to get news from the Dream Team as new developments occur in this exciting area of research.
What's the goal of the project?
To develop transformative therapies for people diagnosed with KRAS mutant lung cancer. Read more»
Who are the sponsors?
American Cancer Society
Bristol-Myers Squibb
Scientific Oversight and Administration
Read more about the sponsors and oversight of the Dream Team
Meet the Dream Team
News
State of the Field in KRAS Research
This article in Chemical & Engineering News features the work of team member Kevan Shokat, PhD.
Have drug hunters finally cracked KRas? After decades of failures, researchers see promise in fresh approaches to developing drugs... Read more »Immunotherapy in the News
During 2015 the U.S. Food and Drug Administration (FDA) approved two immunotherapy drugs for the treatment of non-small cell lung cancer (NSCLC).
On March 4 the FDA expanded the approved use of Opdivo (nivolumab) to treat patients with...
Read more »New SU2C-American Cancer Society Lung Cancer Dream Team Announced
PHILADELPHIA — April 20, 2015 — Stand Up To Cancer (SU2C) and the American Cancer Society (ACS) announced the formation of a $20 million Dream Team to attack the number one cancer killer in America, lung cancer, here today at the...
Read more »